Naresh Parikh, MD
Cardiovascular Disease · Norcross, GANPI 1467409755
Payments from drug & device makers
Across 2,608 payments — averaging $1088.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2.2M
- Seqirus USA Inc$507K
- Genentech, Inc.$48K
- AstraZeneca$30K
- Boehringer Ingelheim$20K
- Pfizer$17K
- plus $15K from 28 others
What the payments were for
- Food & beverage$5,093100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 2,396 | $2,200,765 |
| Seqirus USA Inc | 28 | $506,917 |
| Genentech, Inc. | 13 | $47,576 |
| AstraZeneca | 9 | $30,252 |
| Boehringer Ingelheim | 8 | $20,307 |
| Pfizer | 16 | $16,786 |
| Amgen | 10 | $8,760 |
| Boehringer Ingelheim International GmbH | 2 | $2,745 |
| Novo Nordisk | 33 | $699 |
| Abbott | 18 | $437 |
| Baxter Healthcare | 7 | $303 |
| Johnson & Johnson | 7 | $229 |
| Lilly USA, LLC | 7 | $222 |
| Amarin Pharma, Inc. | 4 | $172 |
| E.r. Squibb & Sons, L.L.C. | 5 | $169 |
| Lantheus Medical Imaging, Inc. | 2 | $162 |
| Merck | 7 | $158 |
| Dexcom, Inc. | 3 | $155 |
| GSK | 1 | $125 |
| Rigel Pharmaceuticals, Inc. | 1 | $125 |
| Boston Scientific | 1 | $121 |
| Ascensia Diabetes Care US Inc. | 1 | $112 |
| Novartis | 6 | $107 |
| Edwards Lifesciences | 4 | $92 |
| Medtronic | 1 | $89 |
| Astellas Pharma US Inc | 6 | $87 |
| Bayer | 1 | $85 |
| Amryt Pharma Holdings Ltd | 4 | $65 |
| Exact Sciences | 2 | $44 |
| Daiichi Sankyo Inc. | 1 | $34 |
| AbbVie | 1 | $21 |
| Stemline Therapeutics Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,837,969 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $151,280 |
| OzempicSemaglutide | 122 | $131,756 |
| JardianceEmpagliflozin | 60 | $67,115 |
| EntrestoSacubitril/Valsartan | 73 | $66,320 |
| FarxigaDapagliflozin Propanediol | 32 | $44,046 |
| RybelsusSemaglutide | 29 | $38,084 |
| XareltoRivaroxaban | 33 | $33,522 |
| JanuviaSitagliptin Phosphate | 32 | $30,148 |
| MounjaroTirzepatide | 25 | $27,219 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $13,399 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $6,081 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 20 | $5,985 |
| Novolog FlexpenInsulin Aspart | 20 | $5,219 |
| Metoprolol Succinate | 388 | $5,118 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,617 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $699 | $169,840151 claims |
| PfizerEliquis, Abrysvo | $16,786 | $157,264162 claims |
| Boehringer IngelheimJardiance | $20,307 | $67,11560 claims |
| NovartisEntresto | $107 | $66,32073 claims |
| AstraZenecaFarxiga, Symbicort | $30,252 | $48,66351 claims |
| Johnson & JohnsonXarelto | $229 | $33,52233 claims |
| MerckJanuvia | $158 | $30,14832 claims |
| Lilly USA, LLCMounjaro | $222 | $27,21925 claims |
| GSKTrelegy Ellipta | $125 | $13,39917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Norcross
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
- Michael MorrisAtlanta$1.1M
- Modele OgunniyiAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.